AzTrials
AzTrials

Wound Healing DelayedNCT05898698

Prospective Case Registry for Wounds

An observational study of Wound Healing Delayed, run by Kerecis Ltd. at 1 site in United States.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This is a post-market, observational and non-interventional registry to collect real-world data in diverse clinical settings and wound applications of acellular fish skin graft (FSG). Read more about this study

Who is it for?
Ages 18 to 90 years
Conditions the study is for
Wound Healing Delayed
How many people
300 participants
Where
1 siteUnited States
Study dates
17 Mar 2023to 17 Dec 2025
How long will I take part?
1 Year
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 90 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Ages above 18 less than 90 years of age who have wounds being treated with FSG.

Who may be able to join

  • Subjects age 18 and older and are able to provide informed consent.
  • Having at least one partial or full thickness wound appropriate for FSG and the wound has NOT received FSG previously.
  • Appropriate wounds include: Partial or full thickness wounds, Diabetic foot ulcers, venous leg ulcers, pressure ulcers, chronic vascular ulcers, Trauma wounds (2nd degree burn, abrasions, lacerations, skin tears.
  • Surgical wounds (donor sites/grafts, post-Mohs surgery, post Laser surgery, podiatric, wound dehiscence

Who cannot join

  • Patient has a 3rd degree burn Patient has a know sensitivity to fish products Patient whose target wound was previously treated with FSG Patient is breastfeeding

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Kerecis

    Arlington, Virginia, 22201

Other trials in United States

About this study

Official title: Prospective Observational Registry of Safety and Effectiveness of Acellular Fish Skin Grafts in Treatment of Cutaneous Wounds

This is a post-market, observational and non-interventional registry to collect real-world data in diverse clinical settings and wound applications of acellular fish skin graft (FSG). The registry will be multi-center , target a wide patient population and a variety of wounds to document the quality of wound care, patient outcomes, safety and long-term results.

Read the detailed description

Introduction: This registry will be conducted according to US standards of Good Clinical Practice as adopted by the Food and Drug Administration, associated Federal regulations and applicable institutional research policies and procedures. This study has been approved by a central IRB, WCG IRB in April 2023.

Registry Objectives: The overall objective of the registry is to collect quality and safety data to assess the efficacy of the FSG in treatment of acute and chronic wounds. The ultimate goal of the registry is to enhance quality of care, patient outcomes and establish a resource to facilitate the use of FSG in treatment of acute and chronic wounds.

Primary Objective: The main purpose of the registry is to evaluate the safety and long-term effectiveness of acellular fish skin grafts in treatment of acute and chronic wounds in a real world setting.

Secondary Objective: To evaluate the clinical and financial benefits of FSG in terms of quality of healing, pain and treatment cost.

Research Design: This registry will prospectively collect data from treatment and follow-up of patients who have undergone procedures where wounds are treated with Kerecis FSG. The registry is a non-experiment, multi-center , single arm, open label study to determine real world long-term safety and quality of Kerecis FSG. The study will not be interventional, de-indentified, HIPAA compliant data will only be collected on patients already scheduled to receive the Kerecis product. Subjects will be enrolled as they are scheduled to receive FSG for treatment of their index wound. Subjects will complete follow up as scheduled by their physician and their data will be documented at weekly follow-ups through week 32. Clinical improvement will be collected through case report forms (CRF) at each time point. Subjects will be followed for the 32 weeks but if the Index wound heals before that time , there will be a Healing Confirmation Visit (HCV) 2 weeks after to confirm the Index wound is still healed. If Index wound is not healed at the HCV then the subject will continue to next weekly visit. Index wound assessments will be captured digitally. The depth of the index wound will be collected manually by using a sterilized cotton swab placed in the deepest part of the wound and documenting that measurement. One year form the procedure, patients will receive a survey to evaluate their overall experience and provide any feedback. Overall, the registry is prospective except information regarding patient medical history can be collected retrospectively.

Registry Procedures: Specific Training: Prior to subject enrollment , the Sponsor will initiate in person training with participating sites to provide training to the physicians and their staff about the protocol, registry procedures and data entry. The sponsor will implement a number of strategies to ensure to ensure the quality, consistency and interpretability of data recorded. Training, education and ongoing liason with participating sites will be provided to support high quality data collection.

Data Management and Quality Plan: Data De-identification: Subjects enroll in the registry will be assigned a unique subject identification number. This number will consist of ten characters for the registry protocol number, three digits for a site number and four digits for a sequentially assigned subject number (i.e.,0001, 0002 etc.) Data confidentiality, storage, and Retention: All clinicians and related medical staff involved in looking after patients during the study are bound by medical confidentiality and are obliged to comply with data protection follow all Health Information Portability and Accountability Act of 1996 (HIPAA) and Protected Health Information (PHI). Data will be collected in a CRF and entered into secure, web-based portal databases. The databases are housed and managed in an International Organization for Standardization (ISO) 27001 certified environment. Only authorized users and site administrators can see site wide data. Surgeon users can only see their procedure. The registry will contain built-in exporting function to enable data extraction by participating sites to help clinicians review their practice and improve the services. The paper form CRF will be stored in a locked file cabinet at the participating sites and will be shredded after 7 years post completion of the registry.

Data Quality: The registry will implement several strategies to maintain data quality and consistency such as routine cleaning, quality check and periodic feedback. Training, education and ongoing liason with participating sites will be provided to supporting high quality data collection.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Primary Endpoint : Complete Wound Closure

    Is time and frequency of complete wound closure by or on 32 weeks. Complete closure is referred to as full epithelialization with the absence of drainage.

    Measured: 32 weeks

Secondary outcomes (7)
  1. Secondary Endpoints : Reduction in wound area

    Proportion of subjects achieving > 60% reduction in wound area from baseline

    Measured: 32 weeks

  2. Reduction in wound depth

    Proportion of subjects achieving >60% reduction in wound depth from baseline

    Measured: 32 weeks

  3. Increase in Vascularization

    Proportion of subjects achieving >20% increase in revascularization ( or tissue oxygen saturation) from baseline using noninvasive imaging technique

    Measured: 32 weeks

  4. Pain medication use

    Proportion of subjects request for pain medication during treatment

    Measured: 32 weeks

  5. Number of applications/Cost

    Average number of FSG applications and average cost per patient until wound closes

    Measured: 32 weeks

  6. Readmission rate

    Number of readmission to hospital for index wound related event(s)

    Measured: 32 weeks

  7. I year follow-up

    12 month outcomes to see if any recurrences at the Index wound

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Jun 2023
  2. Study start17 Mar 2023
  3. Primary completion17 Mar 2025 (estimated)
  4. Study completion17 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
300 participants (estimated)
Target duration
1 Year
IDs, dates and publications
ClinicalTrials.gov ID
NCT05898698
Sponsor's protocol ID
KS-0790
Status last verified
Oct 2024
First submitted
1 Jun 2023
Last updated
30 Dec 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Wound Healing Delayed, run by Kerecis Ltd. at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 30 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Primary Endpoint : Complete Wound Closure (time frame: 32 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Dec 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in